The Epidemiology of Blood Pressure and Its Worldwide Management

Circulation Research

Volumn 116, Issue 6, 2015, Pages 925-935

  Rahimi, Kazem ^a   Emdin, Connor A ^a,b   MacMahon, Stephen ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

blood pressure; epidemiology; hypertension; hypertension management

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; ELEVATED BLOOD PRESSURE; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PREDICTION; PRIORITY JOURNAL; PULSE PRESSURE; REVIEW; SYSTOLIC BLOOD PRESSURE; AGING; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMORBIDITY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIASTOLE; DISEASE MANAGEMENT; ECONOMICS; HEALTH; HEALTH CARE DISPARITY; INCOME; KIDNEY DISEASES; META ANALYSIS (TOPIC); PHYSIOLOGY; RISK FACTOR; SYSTOLE;

AGING; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIASTOLE; DISEASE MANAGEMENT; GLOBAL HEALTH; HEALTHCARE DISPARITIES; HUMANS; HYPERTENSION; INCOME; KIDNEY DISEASES; META-ANALYSIS AS TOPIC; RISK FACTORS; SYSTOLE;

EID: 84930155593     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.304723     Document Type: Review

References (57)

1. Kotchen TA. Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011;58:522-538. doi: 10.1161/HYPERTENSIONAHA.111.177766.
2. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for life insurance. JAMA. 1914;LXIII:1752-1754.
3. Society of Actuaries. Blood Pressure: Report of the Joint Committee on Mortality of the Association of Life Insurance Medical Directors and the Actuarial Society of America. New York, NY.
4. Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham Heart Study. Glob Heart. 2013;8:49-57.
5. Kagan A, Gordon T, Kannel WB, Dawber TR. Proceedings of the Council for High Blood Pressure Research. New York: American Heart Association; 1959.
6. Friedberg C. Diseases of the Heart. Philadelphia, PA: WB Saunders Co; 1949.
7. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
8. Gotto AM Jr. The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. JAMA. 1997;277:595-597.
9. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615.
10. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
11. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504-514.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
13. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-1911. doi: 10.1016/S0140-6736(14)60685-1.
14. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707-716. doi: 10.1097/01.hjh.0000052492.18130.07.
15. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
16. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54:1827-1834. doi: 10.1016/j.jacc.2009.05.073.
17. Davies JE, Whinnett ZI, Francis DP, Manisty CH, Aguado-Sierra J, Willson K, Foale RA, Malik IS, Hughes AD, Parker KH, Mayet J. Evidence of a dominant backward-propagating "suction" wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation. 2006;113:1768-1778. doi: 10.1161/ CIRCULATIONAHA.105.603050.
18. Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 1999;159:2004-2009.
19. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, MacMahon S. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation. 1995;92:2437-2445.
20. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495.
21. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897-2908. doi: 10.1093/eurheartj/ehq328.
22. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18. doi: 10.1056/NEJM199601043340103.
23. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-594.
24. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923-928. doi: 10.1001/ archinte.165.8.923.
25. O'Seaghdha CM, Perkovic V, Lam TH, McGinn S, Barzi F, Gu DF, Cass A, Suh I, Muntner P, Giles GG, Ueshima H, Woodward M, Huxley R; Asia Pacific Cohort Studies Collaboration. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension. 2009;54:509-515. doi: 10.1161/ HYPERTENSIONAHA.108.128413.
26. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol. 1971;27:335-346.
27. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation. 1999;100:354-360.
28. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieère P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension. 1997;30:1410-1415.
29. Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A; Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension. 2003;42:69-75. doi: 10.1161/01. HYP.0000075083.04415.4B.
30. Franklin SS, Gustin W IV, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308-315.
31. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J; MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287:2677-2683.
32. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245-1249.
33. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260. doi: 10.1016/ S0140-6736(12)61766-8.
34. Rahimi K, Macmahon S. Blood pressure management in the 21st century: maximizing gains and minimizing waste. Circulation. 2013;128:2283-2285. doi: 10.1161/CIRCULATIONAHA.113.006218.
35. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-577. doi: 10.1016/S0140-6736(10)62036-3.
36. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518. doi: 10.1016/S0140-6736(08)60655-8.
37. Lloyd-Jones D, Adams RJ, Brown TM, et al;American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
38. Fuchs FD. Why do black Americans have higher prevalence of hypertension?: an enigma still unsolved. Hypertension. 2011;57:379-380. doi: 10.1161/HYPERTENSIONAHA.110.163196.
39. Conen D, Glynn RJ, Ridker PM, Buring JE, Albert MA. Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. Eur Heart J. 2009;30:1378-1384. doi: 10.1093/eurheartj/ehp072.
40. Colhoun HM, Hemingway H, Poulter NR. Socio-economic status and blood pressure: an overview analysis. J Hum Hypertens. 1998;12:91-110.
41. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872.
42. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241. doi: 10.1001/jama.2009.2014.
43. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380:611-619. doi: 10.1016/S0140-6736(12)60861-7.
44. Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43:116-128. doi: 10.1093/ije/dyt215.
45. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators- Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158:1-7.e1. doi: 10.1016/j.ahj.2009.04.019.
46. Chow CK, Teo KK, Rangarajan S, et al; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-968.
47. Yusuf S, Islam S, Chow CK, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243.
48. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105-2114. doi: 10.1161/ CIRCULATIONAHA.112.096156.
49. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383:1912-1919. doi: 10.1016/S0140-6736(14)60688-7.
50. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605. doi: 10.1161/CIRCULATIONAHA.108.830299.
51. Herttua K, Tabák AG, Martikainen P, Vahtera J, Kivimäki M. Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study. Eur Heart J. 2013;34:2933-2939. doi: 10.1093/eurheartj/eht219.
52. Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21:183-188. doi: 10.1038/ajh.2007.33.
53. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117. doi: 10.1136/bmj.39553.670231.25.
54. Howard G, Prineas R, Moy C, Cushman M, Kellum M, Temple E, Graham A, Howard V. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke. 2006;37:1171-1178. doi: 10.1161/01. STR.0000217222.09978.ce.
55. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
56. Blood Pressure Lowering Treatment Trialists' Collaboration, Sundström J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S, Patel A, Perkovic V, Turnbull F, Neal B. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591-598.
57. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128:2309-2317. doi: 10.1161/CIRCULATIONAHA.113.002290.